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Abstract 
Purpose: To demonstrate the effect of resveratrol on Notch signaling in MG-63 and U2OS 
osteosarcoma cell lines.  
Methods: Cell Counting Kit 8 reagent was used to analyze cell proliferation while TRIzol® reagent was 
employed for the extraction of total RNA. High Capacity cDNA reverse transcription chain reaction kit 
was used to transcribe 2 μg RNA. Western blot analysis was performed to examine Hes1 and Hey1 
expression. 
Results: The results revealed that resveratrol treatment exhibited dual mechanisms of action on the 
activation of Notch signaling in osteosarcoma cells. The osteosarcoma cell lines, MG-63 and U2OS, 
when exposed to 20 µM concentration of resveratrol for 48 h showed significant toxicity compared to 
untreated cells. However, 30 µM concentration of resveratrol induced higher toxicity which was lethal to 
cell growth. The results from RT qPCR and Western blot data revealed a concentration-dependent 
effect of resveratrol on the expression of Notch signaling genes including Hes1, Hes5, Hey1, Hey2 and 
HeyL in U2OS cells. Treatment of U2OS cells with 20 µM concentration of resveratrol for 48 h induced a 
marked increase in the expression of Hes1, Hes5, Hey1, Hey2 and HeyL mRNA compared to the 
untreated cells. However, at a concentration of 30 µM, resveratrol inhibited the activation of Notch 
signaling pathway. This was evident by a decrease in the expression of Hes1, Hes5, Hey1, Hey2 and 
HeyL, Notch signaling target genes.  
Conclusion: Resveratrol plays an important role in the activation of Notch signaling pathway and may 
be of therapeutic benefit in the treatment of osteosarcoma. 
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Osteosarcoma one of the frequently detected 
malignant bone tumors in adolescents and 
children is associated with enhanced local 
growth and metastasis [1]. In the USA alone, 
more than 400 new cases of pediatric 
osteosarcoma are detected every year [2]. The 
commonly used treatment strategies for 
osteosarcoma include chemotherapy and 
surgical excision, but the rate of prognosis is very 
poor [3]. Therefore, efforts for discovery and 
screening of novel molecules for osteosarcoma 
treatment are constantly being performed 
throughout the globe. During the last three 
decades various molecules have been 
developed for the treatment of osteosarcoma 
which led to overall survival rate of more than 50 
%. Some of these molecules include 
methotrexate, resveratrol, ifosfamide cisplatin, 
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and etoposide [4]. However, it has been reported 
that patients with metastatic or recurrent tumors 
show poor prognosis [5,6]. Therefore, it is 
believed that knockdown of signaling pathways 
can provide promising results for the treatment of 
osteosarcoma. 
 
The process of proliferation, apoptosis and cell 
differentiation in various types of cancers is 
regulated by Notch signaling pathway [7-9]. It is 
reported that Notch receptors interact with the 
corresponding ligands after cleavage in the 
presence of proteolytic enzymes. These 
alterations induce the secretion of intracellular 
domain of Notch which is translocated to the 
nucleus where it complexes leading to the 
activation of transcription specific target genes 
[10,11]. These target genes include hairy and 
enhancer of split (Hes) and Hes related with 
YRPW motif (Hey). Down-regulation of the 
activity of Notch genes has been detected in 
various malignancies like colon [12,13], 
pancreatic [14,15] and cervical [16] cancer. 
Furthermore, various studies have demonstrated 
reduced activity of Notch in osteosarcoma 
[17,18]. Therefore, the present study was 
designed to investigate the effect of resveratrol 
on the activity of the Notch signaling pathway in 
U2OS osteosarcoma cell lines. 
 
Resveratrol has shown promising results in the 
suppression of cellular events involved in the 
beginning and progression of tumors in several 
types of cells lines [19,20]. It also increases the 
immunity of mice by promoting the expression of 
cytokines including interleukin (IL)-12 and 
interferon (IFN)-γ [21]. In addition, resveratrol 
treatment induces inhibition of cell growth and 
proliferation in breast carcinoma cell lines [22]. 
The synthetic derivatives of resveratrol have also 
been shown to possess potent activity against 
tumor cell lines including MCF-7 human breast 
adenocarcinoma cell line [23,24]. The present 
study demonstrates the effect of resveratrol on 
Notch signaling pathway activation in MG-63 and 
U2OS, osteosarcoma cell lines. The results 
revealed that resveratrol treatment exhibited dual 







Resveratrol was obtained from Sigma (St. Louis, 
MO) and was dissolved in dimethyl sulfoxide 
(DMSO, Sigma) to prepare the stock solution. 
 
Cell lines and culture  
 
Human osteosarcoma cell lines MG-63 and 
U2OS were obtained from the American Type 
Culture Collection (ATCC, Rockville, MD, USA). 
The cells were grown in DMEM with 10 % FBS 
and cultured in 5 % CO2 atmosphere at 37 oC. 
The viability of the cells was analyzed using 
trypan blue staining (Invitrogen Life 
Technologies). 
 
Cytotoxicity assay  
 
MG-63 and U2OS osteosarcoma cells were 
distributed at a density of 2 x 105 cells per well 
onto the 96 well culture plates. To each of the 
well different concentrations of resveratrol were 
added and the cells were cultured for 48 h. The 
control cells were treated with DMSO alone and 
then incubated for 48 h. After incubation, 20 μL 
of the Cell Counting Kit 8 reagent Sigma (St. 
Louis, MO), was added to each well. The cells 
were again incubated for 1 h at 37 oC under 
humidified atmosphere of 5 % CO2. The 
microplate reader (Thermo Fisher Scientific, 
Waltham, MA, USA) was used to measure the 
optical density of each well at 465 nm. 
 
Quantitative polymerase chain reaction 
(qPCR)  
 
From the resveratrol treated or untreated cells, 
total RNA was extracted using TRIzol® reagent 
(Invitrogen Life Sciences, Carlsbad, CA, USA) 
according to the manufacturer's instructions. The 
High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Inc, Foster City, CA, USA) 
was used to transcribe 2 μg RNA samples to 
cDNA according to the manual protocol. 
QuantiTect SYBR Green PCR kit (Qiagen, 
Tokyo, Japan) was used for the quantification of 
transcripts by qPCR whereas the analysis was 
performed using Applied Biosystems® 7500 Fast 
Real Time PCR system (Applied Biosystems 
Inc.). The PCR reactions were carried out at 95 
oC for 10 min, then 40 cycles of 95 oC for 30 sec 
and 60 oC for 1 min. The data obtained was then 
analyzed using ABI Prism® analysis software 
(Applied Biosystems, Inc.).  
 
Western blot analysis 
 
U2OS and Saos 2 cells were washed three times 
with cold PBS and then treated with 120 μl radio-
immuno precipitation assay buffer [50 mM Tris 
HCl, pH 6.8; 0.1% SDS, 150 mM NaCl, 1 mM 
EDTA, 0.1 mM Na3VO4, 1 mM sodium fluoride 
(NaF), 1 % Triton X 100, 1 % NP 40, 1 mM 
dithiothreitol, 1 mM PMSF, 1 μg/mL aprotinin, 1 
μg/mL leupeptin and 1 μg/mL pepstatin A] for cell 
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lysis. Cell lysates were centrifuged at 12,000 x g 
for 30 min to get the clear supernatant. For the 
purpose of the determination of the concentration 
of proteins bicinchoninic acid assay (Sigma 
Aldrich). The proteins were separated by 
electrophoresis on SDS polyacrylamide gel and 
then transferred onto polyvinylidene difluoride 
membranes. The membranes were blocked with 
5 % skimmed milk in buffer [10 mM Tris HCl (pH 
7.6), 100 mM NaCl and 0.1 % (v/v) Tween 20] for 
45 min at 25 oC. The membranes were incubated 
with primary antibodies under cold atmosphere 
overnight. The primary antibodies used were anti 
Hes1, anti Hey1 and anti β actin (BD Biosciences 
Pharmingen). After incubation, Tris buffered 
saline and Tween 20 washed membranes were 
incubated with the secondary antibodies for 2 h. 
The proteins were analyzed by semi quantitation 
using Tanon Gel Imager system (Tanon, 
Shanghai, China). 
 
Statistical analysis  
 
Analysis of the obtained data was performed 
using a statistical software (SPSS Inc, Chicago, 
IL, USA). All the data are presented as mean ± 
standard deviation (SD), and for numerical data 
analysis, Student's t-test or one-way analysis of 
variance (ANOVA) was used. Differences were 




Effect of resveratrol on the osteosarcoma cell 
lines 
 
The osteosarcoma cell lines, MG-63 and U2OS 
were exposed to a range of resveratrol 
concentrations from 5 to 30 µM for various time 
intervals. The results revealed a concentration 
and time dependent increase in toxicity to MG-63 
and U2OS cells. The concentration at which the 
resveratrol induced toxicity in both the cell lines 
was significant compared to untreated cells at 20 
µM after 48 h (p < 0.01; Fig 1). However, when 
MG-63 and U2OS cells were exposed to 30 µM 
concentration of resveratrol for 48 h it induced 
higher toxicity which was lethal to cell growth (p 




Figure 1: Resveratrol treatment reduces the viability of osteosarcoma cells. MG-63 and U2OS osteosarcoma 
cells were exposed to different doses of resveratrol for various time intervals 
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Effect of resveratrol on the expression of 
Notch target genes 
 
We used RT qPCR and western blot analyses to 
examine the effect of resveratrol on the activation 
of Notch signaling pathway. The results from RT 
qPCR analysis revealed a concentration 
dependent effect of resveratrol on the expression 
Notch signaling genes including Hes1, Hes5, 
Hey1, Hey2 and HeyL, in U2OS cells. Treatment 
of U2OS cells with 20 µM concentration of 
resveratrol for 48 h induced a marked increase in 
the expression of Hes1, Hes5, Hey1, Hey2 and 
HeyL mRNA compared to the untreated cells (p 
< 0.05; Fig 2A). These results were further 
confirmed using western blot analysis. 
Inhibition of Notch target gene expression by 
resveratrol at high concentration  
 
Exposure of the U2OS osteosarcoma cells to 
resveratrol at 50 µM concentration led to a 
marked decrease in the expression of Hes1, 
Hes5, Hey1, Hey2 and HeyL, Notch target genes 
(p < 0.05; Fig 3A). To confirm the inhibitory effect 
of resveratrol at 30 µM concentration western 
blot analysis was performed. The results from 
western blot analysis also revealed a significant 
decrease in the expression of Hes1 and Hey1 
genes following 48 h of the resveratrol treatment 
(Fig 3B). 
 
Figure 2: Activation of Notch target genes in osteosarcoma U2OS cells by treatment with 20 μM concentration of 
resveratrol for 48 h. (A) Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) data indicating 
that resveratrol treatment increased the mRNA expression levels of various Notch target genes. (B) Western blot 
data demonstrating that resveratrol treatment increased the mRNA and protein expression levels, respectively, of 
two Notch target genes (Hes1 and Hey1) in a dose-dependent manner. Results are presented as the mean ± 
standard deviation of three independent experiments 
 
 
Figure 3: Suppression of Notch target genes in U2OS osteosarcoma cells by treatment with a toxic dose of 
resveratrol (30 μM) for 48 h. (A) Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and (B) 
western blot results demonstrated that resveratrol treatment resulted in a significant decrease in Notch target 
gene expression levels. Results are presented as the mean ± standard deviation of three independent 
experiments 
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Exposure of the tumor cells to resveratrol led to 
the suppression of cellular processes associated 
with the beginning and progress of tumors 
[19,20]. Resveratrol treatment enhances 
immunity of mice by increasing the expression of 
cytokines like interleukin (IL)-12 and interferon 
(IFN)-γ [21]. In addition, resveratrol treatment 
inhibits cell growth and proliferation in breast 
carcinoma cell lines [22]. The present study 
demonstrates the role of resveratrol in the 
activation of Notch activity in osteosarcoma cells. 
The results from the present study showed that 
resveratrol induced toxicity in MG-63 and U2OS 
osteosarcoma cell lines significantly compared to 
untreated cells at 20 µM concentration after 48 h. 
However, at 30 µM concentration, resveratrol 
induced higher toxicity which was lethal to cell 
growth. 
 
It is reported that Notch activity leads to the 
development of tumors in osteosarcoma cells 
[18]. The activity of Notch1 in osteosarcoma cells 
plays an important role in the process of tumor 
cell invasion and tissue metastasis [25]. Studies 
have been performed which clearly demonstrate 
that downregulation of Notch signaling pathway 
inhibits the proliferation rate of cancer cells in 
vitro and tumor growth in vivo [26].  
 
The present study reveals that resveratrol 
treatment exhibits a concentration dependent 
effect on toxicity in osteosarcoma cells. Exposure 
of the osteosarcoma cells to resveratrol up to 20 
μM significantly increased the expression of 
Hes1, Hes5, Hey1, Hey2 and HeyL, Notch target 
genes after 48 h. These findings revealed that 
concentration of resveratrol required for induced 
activation of Notch signaling pathway is 20 μM.  
 
However, when the osteosarcoma cells were 
exposed to higher concentration (30 μM) of 
resveratrol, the expression levels of Notch genes 
was reduced significantly. Therefore, the data 
from the present study demonstrates that 
resveratrol induced cytotoxicity in the 
osteosarcoma cells at higher doses may be 





Resveratrol exhibits dual role in the activation of 
Notch signaling pathway by promoting its 
activation at low doses and inhibiting it at higher 
doses. Therefore, the drug is a potential 
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